1) World Health Organization Classification Tumours:Tumours of Haematopoietic and Lymphoid Tissues. Ed by Jaffe ES, Harris NL, Stein H, Vardiman, IARC Press, 2001
2) Goldie JH & Coldman AJ:A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733, 1979
3) Klimo P et al:MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102:596-602, 1985
6) Dana BW et al:m-BACOD treatment for intermediate-and high-grade malignant lymphomas:a Southwest Oncology Group Phase II trial. J Clin Oncol 8:1155-1162, 1990
7) Miller TP et al:Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE CytaBOM:A group wide Southwest Oncology Group study. J Clin Oncol 8:1951-1958, 1990
8) De Vita VT et al:The chemotherapy of lymphomas:looking back, moving forward-the Richard and Hinda Rosenthal foundation award lecture. Cancer Res 47:5810-5824, 1987
10) Fisher RI:Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 40 suppl:S42-S46, 1997
13) Wolf M et al:Long-term survival advantage of MACOP-B over CHOP in intermediate garadenon-Hodgkin's lymphoma. The Australian and New Zealand lymphoma group. Ann Oncol 8:71-75, 1997
14) Linch DC et al:A randomized comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma-a British National Lymphoma Investigation report. Br J Cancer 74:318-322, 1996
15) Montserrat E et al:CHOP vs ProMACE-CytaBOM in the treatment of aggressive non Hodgkin lymphoma:long-term results of malticenter randomized trial. (PETHEMA;Spanish cooperative Group for the study of hematologic malignancies treatment. Spanish Society of Hematology. Eur J Haematol 57:377-383, 1996
16) Jerkeman M et al:CHOP versus MACOP-B in aggressive lymphoma-a Nordic Lymphoma Group randomized trial. Ann Oncol 10:1079-1086, 1999
17) Messori A et al:Survival in patients with intermediate or high grade non-Hodgkin's lymphoma:meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 84:303-307, 2001
19) Miller TP et al:CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphoma:update of the Southwest Oncology Group (SWOG) randomized trial. Proc Am Soc Hematol #3024, 2001
20) Horning SJ et al:Final report of E 1484:CHOP v CHOP+radiotherapy for limited stage diffuse aggressive lymphoma. Proc Am Soc Hematol #3023, 2001
21) Shipp MA et al:A predictive model for aggressive NHL:The International Non-Hodgkin's Lymphoma Prognostic Factor Project. N Engl J Med 329:987-997, 1993